PURPOSE: Time to progression (TTP), overall survival, and quality of life (QL) were compared in patients with hormone-resistant prostate cancer (HRPC) treated with prednisone (5 mg orally, four times ...

Akeega, the first dual action tablet with a PARP inhibitor and abiraterone acetate, was approved for the treatment of patients with suspected or confirmed BRCA-positive metastatic castration-resistant ...

Correlation between product parameters and overall survival in three trials of sipuleucel-T, an autologous active cellular immunotherapy for the treatment of prostate cancer. Background: Docetaxel ...

Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer RARITAN, N.J., ...

ZYTIGA(R) Plus Prednisone Demonstrates Statistically Significant Overall Survival After 49-Month Follow-Up Analysis in Chemotherapy-Naïve Men with Metastatic Castration-Resistant Prostate Cancer ...

Credit: Getty Images. The application is supported by data from a phase 3 study evaluating niraparib plus AAP as first-line treatment in patients with mCRPC with or without alterations in HRR ...

Janssen Research & Development announced that it has unblinded the Phase 3 study of Zytiga (abiraterone acetate) plus prednisone for the treatment of asymptomatic or mildly symptomatic patients with ...

J&J JNJ announced that the European Commission has approved its precision therapy, Akeega (niraparib and abiraterone acetate dual action tablet), for expanded use in prostate cancer. The regulatory ...

With nearly one-year of additional follow-up, adding Keytruda to the combination of abiraterone acetate and the steroid prednisone shows continued benefit in men with metastatic castration-resistant ...

RAHWAY, N.J.--(BUSINESS WIRE)--AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that a supplemental New Drug Application (sNDA) for LYNPARZA in ...